Nov 7, 2026 · 30 min
China pushes biotech from fast development to first-in-class innovation
Ep. 396 - China’s first-order innovation
China’s biotech rise is forcing global drug developers to rethink where they discover, test, finance, and commercialize medicines.
- 1China combines faster regulatory review, dense patient populations, and large hospitals to accelerate early clinical development.
- 2The COINS Act could reshape U.S.-linked investment, prompting licensing-like structures and milestone-based financing strategies.
- 3China’s next challenge is translating first-in-class biology into globally synchronized development, reimbursement, and commercial success.
Don't miss
Weihao Xu describes receiving approval within 30 calendar days through China’s newer regulatory pathway, illustrating the country’s clinical-development speed.
The brief
Recorded live in Shanghai, the panel brings together Simone Fishburne, Weihao Xu, Matthew Hewitt, Jack O’Meara, and Josh Berlin to examine China’s expanding role in biotech.
The case for a China strategy rests on speed and scale: shorter IND timelines, dense patient populations, large hospitals, and clinical infrastructure that can support rapid early development.
The COINS Act adds uncertainty to cross-border investment, while companies and investors consider licensing-like deals, milestone-based tranches, and new structures for preserving collaboration.
Weihao Xu describes receiving approval within 30 calendar days under China’s newer pathway, a concrete example of how regulatory changes can alter trial-location decisions.
The panel’s broader argument is that first-in-class assets are emerging from China, but global success will require regulatory alignment, synchronized trials, stronger partnerships, and better reimbursement.
What was said on this episode
14 statements · 12 positive · 1 negative · 1 neutral
China is producing a meaningful and growing signal of first-in-class assets
“what we're now seeing is a very real signal of first in class assets”
Listen at 17:54
First-in-class assets are not yet a majority of China biotech assets
“it's not yet a majority, but it's a very real signal”
Listen at 18:47
China’s underlying first-order innovation will continue increasing
“the stuff under the surface, there's more and more. And that's what we really expect to see.”
Listen at 18:55
Western competitors often underestimate China’s first-order innovation
“that is overlooked quite often by competitors in the West as to the amount of actual what we call first order innovation in China”
Listen at 19:00
- Jack O’Mearaon China first-in-class assetsPositive19:28
The rise of first-in-class assets in China is inevitable
“that rise of first-in-class is very real and inevitable”
Listen at 19:28
China’s challenge is translating innovative biology into development programs
“the issue for China, which is not different than anywhere else actually, is going to be their ability to convert that or to translate that into programs”
Listen at 19:45
Many new China biotech companies are emerging
“there are so many new China biotechs emerging”
Listen at 20:26
More deals involving unfamiliar China biotechs are forthcoming
“there's going to be a lot of who are these guys kind of deals coming up by biotechs probably most of our audience has never heard of”
Listen at 20:46
- Weihao Xuon China clinical research ecosystemPositive21:53
China’s ecosystem advances physician-led clinical innovation
“the China ecosystem take those innovative ideas to the next level”
Listen at 21:53
- Weihao Xuon China investigator-initiated trialsPositive21:58
China can conduct investigator-initiated trials at scale
“The IIT can be run in scale”
Listen at 21:58
- Matthew Hewitton China pharmaceutical developmentPositive23:16
China has shifted from generics toward innovative compounds
“we've seen over the last six, seven years a real ramp here in China away from more generics and into more innovative compounds”
Listen at 23:16
- Matthew Hewitton China biotech talentPositive23:29
A substantial talent influx returned from the United States to China
“there was certainly a talent surge back into China from a lot of the U.S.”
Listen at 23:29
Korea will produce more new companies and deals
“you're going to be hearing a lot more Nucos. You're going to be hearing a lot more deals.”
Listen at 28:51
Investors should engage with Korea’s biotech opportunity early
“don't be late to the Korea story”
Listen at 28:57
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.